"We're going to have people, for one reason or another, who either don't want an injection at this point, or are just looking for a different alternative," Primack told CNBC in an interview in March
You may have witnessed the excitement surrounding the new classes of medications being used for weight loss: GLP-1 receptor agonists, like Wegovy and Ozempic, and the newer, dual action (GLP1/GIP) medications like Mounjaro and Zepbound
The trials were registered at ClinicalTrials.gov (trial identifiers NCT02172313 and NCT01572753)
A 2022 consensus statement established a new definition and diagnostic criteria for sarcopenic obesity
There is no single number that applies to every patient
Are there side effects with oral GLP-1 therapy